Lamster I B, Holmes L G, Gross K B, Oshrain R L, Cohen D W, Rose L F, Peters L M, Pope M R
Division of Periodontics, Columbia University School of Dental and Oral Surgery, New York, New York, USA.
J Clin Periodontol. 1995 Jan;22(1):36-44. doi: 10.1111/j.1600-051x.1995.tb01768.x.
Analysis of gingival crevicular fluid (GCF) offers a non-invasive means of studying the host response in periodontal disease, and may provide an early indication of the patient at risk for active periodontitis. A number of host markers have been studied for their relationship to disease activity (probing attachment loss or PAL). GCF levels of the acid glycohydrolase beta-glucuronidase (beta G), a marker of primary granule release from polymorphonuclear leukocytes (PMN), have been shown to identify patients with periodontitis at risk for additional PAL. In this multicenter trial, we evaluated (a) the short-term effect of conservative periodontal therapy on beta G activity in GCF, and (b) the relationship of persistently elevated beta G activity to PAL in patients who were monitored for 6 months. The study population included a total of 140 patients with chronic adult periodontitis. 130 patients were on a regular recall schedule, and 10 were previously untreated. After collection of baseline clinical data at all sites, and analysis of beta G in GCF from one site (mesiobuccal) per tooth, the patients received a scaling and prophylaxis. Two weeks later patients were seen for collection of GCF. If elevated enzyme activity was found at 2 weeks, the patients were seen at 3 months for a clinical exam and GCF collection. Clinical parameters were collected from all patients at 6 months. Therapy tended to reduce beta G activity in GCF.(ABSTRACT TRUNCATED AT 250 WORDS)
龈沟液(GCF)分析提供了一种研究牙周疾病中宿主反应的非侵入性方法,并且可能为有活动性牙周炎风险的患者提供早期指示。已经研究了许多宿主标志物与疾病活动(探诊附着丧失或PAL)的关系。酸性糖水解酶β-葡萄糖醛酸酶(βG)是多形核白细胞(PMN)初级颗粒释放的标志物,其龈沟液水平已被证明可识别有额外附着丧失风险的牙周炎患者。在这项多中心试验中,我们评估了(a)保守牙周治疗对龈沟液中βG活性的短期影响,以及(b)在接受6个月监测的患者中,持续升高的βG活性与附着丧失的关系。研究人群包括总共140例慢性成人牙周炎患者。130例患者按常规复诊计划进行,10例患者此前未接受治疗。在收集所有部位的基线临床数据,并分析每颗牙齿一个部位(近中颊侧)龈沟液中的βG后,患者接受了龈上洁治和预防性治疗。两周后对患者进行龈沟液采集。如果在2周时发现酶活性升高,则在3个月时对患者进行临床检查和龈沟液采集。在6个月时收集所有患者的临床参数。治疗倾向于降低龈沟液中βG的活性。(摘要截短为250字)